Literature DB >> 17664268

Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis.

Vincent E Weynants1, Christiane M Feron, Karine K Goraj, Martine P Bos, Philippe A Denoël, Vincent G Verlant, Jan Tommassen, Ian R A Peak, Ralph C Judd, Michael P Jennings, Jan T Poolman.   

Abstract

Neisseria meningitidis serogroup B is a major cause of bacterial meningitis in younger populations. The available vaccines are based on outer membrane vesicles obtained from wild-type strains. In children less than 2 years old they confer protection only against strains expressing homologous PorA, a major, variable outer membrane protein (OMP). We genetically modified a strain in order to eliminate PorA and to overproduce one or several minor and conserved OMPs. Using a mouse model mimicking children's PorA-specific bactericidal activity, it was demonstrated that overproduction of more than one minor OMP is required to elicit antibodies able to induce complement-mediated killing of strains expressing heterologous PorA. It is concluded that a critical density of bactericidal antibodies needs to be reached at the surface of meningococci to induce complement-mediated killing. With minor OMPs, this threshold is reached when more than one antigen is targeted, and this allows cross-protection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17664268      PMCID: PMC2168297          DOI: 10.1128/IAI.00411-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  A common conserved amino acid motif module shared by bacterial and intercellular adhesins: bacterial adherence mimicking cell cell recognition?

Authors:  Maria Scarselli; Rino Rappuoli; Vincenzo Scarlato
Journal:  Microbiology (Reading)       Date:  2001-02       Impact factor: 2.777

2.  Global epidemiology of meningococcal disease and vaccine efficacy.

Authors:  Andrew J Pollard
Journal:  Pediatr Infect Dis J       Date:  2004-12       Impact factor: 2.129

3.  Common antigenic domains in transferrin-binding protein 2 of Neisseria meningitidis, Neisseria gonorrhoeae, and Haemophilus influenzae type b.

Authors:  P Stevenson; P Williams; E Griffiths
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

4.  Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection.

Authors:  D Martin; N Cadieux; J Hamel; B R Brodeur
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

5.  Identification and characterisation of a novel conserved outer membrane protein from Neisseria meningitidis.

Authors:  I R Peak; Y Srikhanta; M Dieckelmann; E R Moxon; M P Jennings
Journal:  FEMS Immunol Med Microbiol       Date:  2000-08

6.  Allelic diversity of the two transferrin binding protein B gene isotypes among a collection of Neisseria meningitidis strains representative of serogroup B disease: implication for the composition of a recombinant TbpB-based vaccine.

Authors:  B Rokbi; G Renauld-Mongenie; M Mignon; B Danve; D Poncet; C Chabanel; D A Caugant; M J Quentin-Millet
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

Review 7.  Towards an improved serogroup B Neisseria meningitidis vaccine.

Authors:  Kirsten P Perrett; Andrew J Pollard
Journal:  Expert Opin Biol Ther       Date:  2005-12       Impact factor: 4.388

Review 8.  Biogenesis of the Gram-negative bacterial outer membrane.

Authors:  Martine P Bos; Jan Tommassen
Journal:  Curr Opin Microbiol       Date:  2004-12       Impact factor: 7.934

9.  MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain.

Authors:  Philipp Oster; Diana Lennon; Jane O'Hallahan; Kim Mulholland; Stewart Reid; Diana Martin
Journal:  Vaccine       Date:  2005-03-18       Impact factor: 3.641

10.  Cloning and characterization of Neisseria meningitidis genes encoding the transferrin-binding proteins Tbp1 and Tbp2.

Authors:  M Legrain; V Mazarin; S W Irwin; B Bouchon; M J Quentin-Millet; E Jacobs; A B Schryvers
Journal:  Gene       Date:  1993-08-16       Impact factor: 3.688

View more
  41 in total

Review 1.  Identification and characterization of gonococcal iron transport systems as potential vaccine antigens.

Authors:  C N Cornelissen
Journal:  Future Microbiol       Date:  2008-06       Impact factor: 3.165

2.  Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity.

Authors:  Wendell D Zollinger; Elizabeth E Moran; Deborah H Schmiel
Journal:  Clin Vaccine Immunol       Date:  2009-10-14

3.  A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines.

Authors:  Oliver Koeberling; Isabel Delany; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

4.  Phase variation mediates reductions in expression of surface proteins during persistent meningococcal carriage.

Authors:  Mohamed Alamro; Fadil A Bidmos; Hannah Chan; Neil J Oldfield; Emma Newton; Xilian Bai; Jack Aidley; Rory Care; Claire Mattick; David P J Turner; Keith R Neal; Dlawer A A Ala'aldeen; Ian Feavers; Ray Borrow; Christopher D Bayliss
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

Review 5.  A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C.

Authors:  Yordanka Masforrol; Jeovanis Gil; Darien García; Jesús Noda; Yassel Ramos; Lázaro Betancourt; Osmany Guirola; Sonia González; Boris Acevedo; Vladimir Besada; Osvaldo Reyes; Luis Javier González
Journal:  Hum Vaccin Immunother       Date:  2017-10-30       Impact factor: 3.452

6.  Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.

Authors:  Deborah H Schmiel; Elizabeth E Moran; Paul B Keiser; Brenda L Brandt; Wendell D Zollinger
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

7.  An outer membrane receptor of Neisseria meningitidis involved in zinc acquisition with vaccine potential.

Authors:  Michiel Stork; Martine P Bos; Ilse Jongerius; Natasja de Kok; Ingrid Schilders; Vincent E Weynants; Jan T Poolman; Jan Tommassen
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

8.  Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response.

Authors:  V Weynants; P Denoël; N Devos; D Janssens; C Feron; K Goraj; P Momin; D Monnom; C Tans; A Vandercammen; F Wauters; Jan T Poolman
Journal:  Infect Immun       Date:  2009-03-16       Impact factor: 3.441

9.  A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups.

Authors:  Peter T Beernink; Carla LoPasso; Antonella Angiolillo; Franco Felici; Dan Granoff
Journal:  Mol Immunol       Date:  2009-03-14       Impact factor: 4.407

Review 10.  Pathogenic neisseriae: surface modulation, pathogenesis and infection control.

Authors:  Mumtaz Virji
Journal:  Nat Rev Microbiol       Date:  2009-04       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.